racemic-Zanubrutinib-racemic-BGB-3111-DataSheet-生命科学试剂-MedChemExpress_第1页
racemic-Zanubrutinib-racemic-BGB-3111-DataSheet-生命科学试剂-MedChemExpress_第2页
racemic-Zanubrutinib-racemic-BGB-3111-DataSheet-生命科学试剂-MedChemExpress_第3页
全文预览已结束

下载本文档

版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领

文档简介

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemE()-ZanubrutinibCat. No.: HY-101474CAS No.: 1633350-06-7Synonyms: ()-BGB-3111分式: CHNO分量: 471.55作靶点: Btk作通路: Protein Tyrosine Kinase/RTK储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO : 30 mg/m

2、L (63.62 mM)Ethanol : 10 mg/mL (21.21 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 2.1207 mL 10.6033 mL 21.2067 mL5 mM 0.4241 mL 2.1207 mL 4.2413 mL10 mM 0.2121 mL 1.0603 mL 2.1207 mL请根据产品在不同溶剂中的溶解度,选择合适的溶剂配制储备液,并请注意储备液的保存式和期限。体内实验请根据您的实验动物和给药式选择适当的溶解

3、案,配制前请先配制澄清的储备液,再依次添加助溶剂(为保证实验结果的可靠性,体内实验的作液,建议您现现配,当天使;澄清的储备液可以根据储存条件,适当保存;以下溶剂前的百分 指该溶剂在您配制终溶液中的体积占):1. 请依序添加每种溶剂: 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (5.30 mM); Clear solution2. 请依序添加每种溶剂: 10% DMSO 90% (20% SBE-CD in saline)1/2 Master of Small Molecules 您边的抑制剂师www.MedC

4、hemESolubility: 2.5 mg/mL (5.30 mM); Clear solution3. 请依序添加每种溶剂: 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (5.30 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 ()-Zanubrutinib种有效的选择性 Brutons 酪氨酸激酶 (Btk) 抑制剂。体外研究 In both biochemical and cellular assays, ()-Zanubrutinib demonstrates nanomolar Btk inhibiti

5、on activity. Inseveral MCL and DLBCL cell lines, ()-Zanubrutinib inhibits BCR aggregation-triggered Btkautophosphorylation, blocks downstream PLC-2 signaling, and potently inhibits cell proliferation. Incomparison with ibrutinib, ()-Zanubrutinib shows much more restricted off-target activities again

6、st a panel ofkinases, including ITK. ()-Zanubrutinib is at least 10-fold weaker than ibrutinib in inhibiting rituximab inducedADCC, consistent with its weak ITK inhibition activity 1.体内研究 ()-Zanubrutinib induces dose-dependent anti-tumor effects against REC-1 MCL xenografts engrafted eithersubcutane

7、ously or systemically via tail vein injection in mice. In the subcutaneous xenografts. Preliminary 14-day toxicity study in rats shows that ()-Zanubrutinib is very well tolerated and maximal tolerate dose (MTD)is not reached when it is dosed up to 250mg/kg/day 1.户使本产品发表的科研献 Dr. Wang from Chinese Aca

8、demy of Sciences.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Na L, et al. BGB-3111 is a novel and highly selective Brutons tyrosine kinase (BTK) inhibitor. abstract. In: Proceedings of the 106thAnnual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res2015;75(15 Suppl):Abstract nr 2597. doi:10.1158/1538-7445.AM2015-2597McePdfHeightCaution: Product has not been fully validated for medical applic

温馨提示

  • 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
  • 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
  • 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
  • 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
  • 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
  • 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
  • 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

评论

0/150

提交评论